Written by Josh Hardman and Noah Smith with support from Editor-at-Large and patent attorney Graham Pechenik of Calyx Law. In December 2022 a small group of MAPS PBC’s (now Lykos Therapeutics) employees, consultants and lawyers oversaw the filing of the first in a series of four provisional patent applications seeking to cover MDMA having specific particle sizes (US63/


Previous articleWhy Are Some Parents Choosing Psychedelics Over SSRIs for Teens?
Next articlePα+ Psychedelic Bulletin #164: Lykos Dominates News Cycle; EPIsoDE Trial Readout; EU Drug Report Discusses Psychedelics; DEA Should Improve RFRA Petition Process; Other News